Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study
The largest documented PIBD cohort switching to SC-IFX to date showed high treatment persistence at 1 year, confirming SC-IFX as an effective and safe maintenance alternative to IV-IFX.
Authors
- David C. Wilson (ORCID: https://orcid.org/0000-0003-0831-1842)
- Shaden Mahmmod
- Laura Gianolio (ORCID: https://orcid.org/0009-0003-1189-9373)
- Lissy L. de Ridder
- Katherine Armstrong
- J C H Escher
- S Pochesci
- Esmée Helen Boute
- Richard Kay Russell
- Paul Henderson
Institutions
- Leiden University Medical Center (NL)
- Royal Hospital for Children (GB)
- University Medical Center Utrecht (NL)
- Royal Hospital for Sick Children (GB)
- Willem-Alexander Kinderziekenhuis (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Centre for Inflammation Research (GB)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1093/ibd/izaf335
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00